Participant flow

Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients · Source last updated 2024-12-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Nivolumab 360 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IIIA N2-NSCLC adult patients followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months Nivolumab 360 mg: Nivolumab 360 mg IV Q3W + Followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months Paclitaxel 200mg/m2: Paclitaxel 200mg/m2 IV Q3W Carboplatin AUC 6: Carboplatin AUC 6 IV Q3W

   id

   FG000

   title

   Arm 1

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         46

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         46

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice